Brightside Health also announced the appointment of industry titan Trip Hofer to the Board of Directors to advise on go-to-market strategy and execution. This news builds on the company's recent momentum, including new and expanded payer partnerships to support Medicaid and Medicare lives and notable results for its award-winning Crisis Care program for individuals with elevated suicide risk.

Brightside Health serves people with mild to severe clinical depression, anxiety, and other mood disorders, including those with elevated suicide risk, through precision psychiatry, clinically proven therapy, and Crisis Care. The impressive activity and results attracted lead investor S32, along with Kennedy Lewis, Time BioVentures, and Anne Wojcicki (Redwood Pacific). Existing investors ACME, Mousse Partners, and Triventures also contributed to the raise of $33M, an intentional amount that will be used to fuel Brightside Health's growth into new markets and new offerings.

Brightside Health delivers life-saving mental health care to people with mild to severe clinical depression, anxiety, and other mood disorders, including those with elevated suicide risk. Powered by proprietary AI, purpose-built technology, and a world-class clinician network, Brightside Health combines precision psychiatry and leading-edge therapeutic techniques to improve patient outcomes across the entire clinical spectrum, affordably and at scale. Brightside Health can be paid for with insurance in all 50 states and D.C., with appointments available in 48 hours or less.